Charles McKhann - Silk Road Chief Officer
SILKDelisted Stock | USD 27.49 0.00 0.00% |
Executive
Charles McKhann is Chief Officer of Silk Road Medical
Age | 55 |
Phone | 408 720 9002 |
Web | https://silkroadmed.com |
Silk Road Management Efficiency
The company has return on total asset (ROA) of (0.1411) % which means that it has lost $0.1411 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3645) %, meaning that it created substantial loss on money invested by shareholders. Silk Road's management efficiency ratios could be used to measure how well Silk Road manages its routine affairs as well as how well it operates its assets and liabilities.Silk Road Medical currently holds 84.63 M in liabilities with Debt to Equity (D/E) ratio of 1.37, which is about average as compared to similar companies. Silk Road Medical has a current ratio of 6.78, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Silk Road's use of debt, we should always consider it together with its cash and equity.
Similar Executives
Showing other executives | EXECUTIVE Age | ||
Shana Zink | Treace Medical Concepts | N/A | |
Matthew Link | Sight Sciences | 50 | |
Manohar Raheja | Sight Sciences | N/A | |
Jrme Erath | Pulmonx Corp | N/A | |
Jonathan Friedman | Paragon 28 | 53 | |
Rebecca Williston | Rxsight | N/A | |
Frank Vizesi | Orthofix Medical | N/A | |
Nick Corcoran | TransMedics Group | 42 | |
Aimee Einstein | Si Bone | N/A | |
Daniel JD | Orthopediatrics Corp | 55 | |
Aaron Berutti | Treace Medical Concepts | 46 | |
Julie Andrews | Orthofix Medical | 54 | |
Martha MD | Neuropace | 68 | |
Taylor Erickson | Treace Medical Concepts | N/A | |
Trui Hebbelinck | LivaNova PLC | 52 | |
Deanna Wilke | LivaNova PLC | N/A | |
Alex Huang | Rxsight | N/A | |
Kelley Nicholas | Neuropace | N/A | |
Caroline Vaughn | Rxsight | N/A | |
Ray Garrison | Orthopediatrics Corp | N/A | |
John Borrell | Inari Medical | 57 |
Management Performance
Return On Equity | -0.36 | |||
Return On Asset | -0.14 |
Silk Road Medical Leadership Team
Elected by the shareholders, the Silk Road's board of directors comprises two types of representatives: Silk Road inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Silk. The board's role is to monitor Silk Road's management team and ensure that shareholders' interests are well served. Silk Road's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Silk Road's outside directors are responsible for providing unbiased perspectives on the board's policies.
Erica Rogers, President CEO, Director | ||
Sumaira Macdonald, Chief Medical Officer | ||
Mhairi Jones, VP Accounting | ||
Sumaira MD, Executive Director | ||
Kevin Ballinger, Chief Sec | ||
Tammy Leitsinger, Compliance Affairs | ||
Kevin Klemz, Chief EVP | ||
Alison Highlander, Vice Resources | ||
Jorge OHara, Business Marketing | ||
Charles McKhann, Chief Officer | ||
Richard Ruedy, Executive Vice President - Regulatory Affairs, Clinical Affairs & Quality Assurance | ||
Lucas Buchanan, CFO COO | ||
Lynn Lewis, Investors Officer | ||
Andrew Davis, Chief Officer | ||
Matthew McCarthy, Vice Marketing |
Silk Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Silk Road a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.36 | |||
Return On Asset | -0.14 | |||
Profit Margin | (0.30) % | |||
Operating Margin | (0.34) % | |||
Current Valuation | 1.02 B | |||
Shares Outstanding | 40.63 M | |||
Shares Owned By Insiders | 4.15 % | |||
Shares Owned By Institutions | 97.46 % | |||
Number Of Shares Shorted | 3.15 M | |||
Price To Book | 7.22 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Silk Stock
If you are still planning to invest in Silk Road Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Silk Road's history and understand the potential risks before investing.
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data |